30194-54-8

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Pyridin-2-ylpiperazin-1-yl)ethanamine is used as a therapeutic agent for the treatment of psychiatric and neurological disorders. Its agonistic action on the 5-HT2C receptor makes it a potential candidate for managing conditions such as schizophrenia, anxiety, and depression.
Used in Neuropharmacology Research:
2-(4-Pyridin-2-ylpiperazin-1-yl)ethanamine is used as a research compound to study the role of the 5-HT2C receptor in various brain functions and disorders. This helps in understanding the receptor's involvement in mental health and the development of new treatments for related conditions.
Used in Weight Regulation and Metabolic Studies:
2-(4-Pyridin-2-ylpiperazin-1-yl)ethanamine is used as a modulator of food intake and weight regulation. Its potential role in these areas is being investigated for the development of treatments for obesity and related metabolic disorders.

InChI:InChI=1/C11H18N4/c12-4-6-14-7-9-15(10-8-14)11-3-1-2-5-13-11/h1-3,5H,4,6-10,12H2

Upstream product

• 117992-73-1 2-(2-(4-(pyridin-2-yl)piperazin-1-yl)ethyl)isoindoline-1,3-dione 
• 34803-66-2 1-(2-pyridyl)piperazine 
• 33386-11-7 2-(4-(pyridin-2-yl)piperazin-1-yl)acetonitrile 
• 192130-34-0 tert-butyl 4-(2-aminoethyl)piperazine-1-carboxylate 
• 302557-33-1 benzyl N-[2-(piperazin-1-yl)ethyl]carbamate 

Downstream Products

• 697287-72-2 [2-(4-pyridin-2-yl-piperazin-1-yl)-ethyl]-[3-(2-trifluoromethyl-phenyl)-isoxazol-5-ylmethyl]-amine 
• 1240266-65-2 C₂₄H₃₁N₅O*ClH 

Relevant academic research and scientific papers

COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS

The disclosure provides compounds of Formula I (Formula I) (c) And the pharmaceutically acceptable salts thereof. The A, B, C, and D rings and the variables, RA, RB, RC, RD, L0, L1, L2

Small-Molecule Inhibition of the UNC119–Cargo Interaction

N-Terminal myristoylation facilitates membrane binding and activity of proteins, in particular of Src family kinases, but the underlying mechanisms are only beginning to be understood. The chaperones UNC119A/B regulate the cellular distribution and signal

Further delineation of hydrophobic binding sites in dopamine D 2/D3 receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5, 6,7,8-tetrahydro-naphthalen-2-ol

Here we report a structure-activity relationship (SAR) study of analogues of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro- naphthalen-2-ol. Our SAR is focused on introduction of various substitutions in the piperazine ring of the hybrid template. The goal behind this study is to delineate the nature of the binding pocket for N-aryl substitution in the piperazine ring by observing the effect of various hydrophobic and other heteroaromatic substitutions on binding affinity (Ki), as measured with tritiated spiperone and HEK-293 cells expressing either D2 or D3 receptors. Functional activity of selected compounds was assessed with the GTPγS binding assay. Compound 8d was the most selective for the D3 receptor in the spiperone binding assay. An interesting similarity in binding affinity was observed between isoquinoline derivative D-301 and the 2-substituted pyridine derivative 8d, suggesting the importance of relative spatial relationships between the N-atom of the ligand and the molecular determinants of the binding pocket in D2/D3 receptors. Functional activity assays demonstrated high potency and selectivity of (+)-8a and (-)-28b (D2/D3 (ratio of EC50): 105 and 202, respectively) for the D3 receptor and both compounds were more selective compared to the reference drug ropinirole (D2/D3 (ratio of EC50): 29.5).

Synthesis and biological evaluation of oxazole derivatives as T-type calcium channel blockers

T-type calcium channel is one of therapeutic targets for the treatment of cardiovascular diseases and neuropathic pain. In this study, as a part of our ongoing efforts to develop potent T-type calcium channel blockers, we designed oxazole derivatives subs

3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula (I) wherein R1, R2, R3, R4, RA, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.

Synthesis and biological evaluation of novel T-type Ca2+ channel blockers

A small molecule library of piperazinylalkylisoxazole derivatives containing about 600 compounds was designed, synthesized and evaluated for blocking effects on T-type Ca2+ channel. Several ligands were identified to possess high inhibitory activity against the T-type Ca 2+ channel. The compound 21 with trifluoromethyl substituents at C3-position of phenyl group (R1) and C2- position of phenyl group (R2) showed the highest inhibitory activity with IC50 value of 1.02μM, which is comparable to that of mibefradil.

1H,3H-pyrrolo[1,2-c]thiazole derivatives having anti-allergic and anti-inflammatory activity

New compounds of the formula STR1 in which R1 and R2 =H or alkyl and (a) R=CN or alkylcarbonyl, or (b) R=CON(R3)R4, in which R3 =H and R4 =NH2, alkylamino, dialkylamino, phenylam